Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech

Executive Summary

Begins clinical trials of an AIDS vaccine based on a recombinant form of the gp 120 envelope protein as a potential treatment for HIV infection. According to Genentech, the study "is being conducted to determine if post-exposure immunization with recombinant gp 120 can significantly boost the immune system of persons infected with HIV." The trial is being conducted at Walter Reed Army Institute of Research in Washington, D.C., and will involve 55 patients studied over a 10-month period. Genentech also reports the company "is currently evaluating the possibility of a separate human pilot study to test recombinant gp 120 as a potential vaccine to protect uninfected individuals against HIV infection".

You may also be interested in...



Televise The COVID-19 Vaccine Advisory Committee Meetings

With the meetings available on television, access can be assured for just about everyone, and the US FDA can avoid another gut punch to its credibility.

'Sakigake' Treatment Gives Enhertu Rapid Japan OK For Gastric Cancer

Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.

Finance Watch: Five More Biopharma IPOs In The US Raise $624.7m

Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel